Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Dihydrotestosterone and Free/Total Prostatic Specific Antigen Ratio in Diagnosis and Prognosis of Prostatic Disease

View through CrossRef
Background: Both benign prostatic hyperplasia (BPH) and prostate cancer (Pca) include prostate enlargement. The second most common cancer among men worldwide is prostate cancer. It has been documented that by the time they reach their 60s, most men will experience benign prostatic hyperplasia. There is a real difficulty differentiating between benign prostatic hyperplasia and prostate cancer, the prostatic specific antigen (PSA) is not used as a reliable marker of prostate cancer. It is a specific biomarker measure specific to prostate tissues and not prostate cancer. Aims In the analysis of the gray zone of tPSA (4-10 ng/ml), add these biochemical markers and differentiate the root cause of prostate tumor in order to minimize painful and intrusive prostate biopsy. Materials and Methods: A cross-sectional and case control study. It included 110 patients ages range (45-81 years) with benign prostatic hyperplasia (n=55) and prostate cancer (n=55). Forty -five apparently healthy subjects were also included as controls. Peripheral blood samples from controls and patients were collected before obtaining a prostatic biopsy from patients. Serum samples were used for measurements of total Prostate Specific Antigen (tPSA), Free Prostate Specific Antigen (fPSA), and Dihydrotestosterone (DHT) by using ELISA technique. Result: Mean (±SD) serum tPSA and fPSA values for Pca were substantially improved compared to both BPH and control (p=0.001 for all), while mean fPSA/tPSA values for PCa were significantly decreased compared to BPH and control values (p=0.001). In PCa, the mean +SD value of the DHT ratios was significantly lower than in each BHP, and controls (P<0.001) were significantly lower in PCa than in each BHP and regulation (P<0.001). The mean DHT values for BPH were significantly higher as compared to control values (p< 0.001). Conclusion: The level of serum tPSA is 4.2 ng/ml for prostate tumor screening, while 10.1 ng/ml for PCa and BPH differentiation.
Title: Dihydrotestosterone and Free/Total Prostatic Specific Antigen Ratio in Diagnosis and Prognosis of Prostatic Disease
Description:
Background: Both benign prostatic hyperplasia (BPH) and prostate cancer (Pca) include prostate enlargement.
The second most common cancer among men worldwide is prostate cancer.
It has been documented that by the time they reach their 60s, most men will experience benign prostatic hyperplasia.
There is a real difficulty differentiating between benign prostatic hyperplasia and prostate cancer, the prostatic specific antigen (PSA) is not used as a reliable marker of prostate cancer.
It is a specific biomarker measure specific to prostate tissues and not prostate cancer.
Aims In the analysis of the gray zone of tPSA (4-10 ng/ml), add these biochemical markers and differentiate the root cause of prostate tumor in order to minimize painful and intrusive prostate biopsy.
Materials and Methods: A cross-sectional and case control study.
It included 110 patients ages range (45-81 years) with benign prostatic hyperplasia (n=55) and prostate cancer (n=55).
Forty -five apparently healthy subjects were also included as controls.
Peripheral blood samples from controls and patients were collected before obtaining a prostatic biopsy from patients.
Serum samples were used for measurements of total Prostate Specific Antigen (tPSA), Free Prostate Specific Antigen (fPSA), and Dihydrotestosterone (DHT) by using ELISA technique.
Result: Mean (±SD) serum tPSA and fPSA values for Pca were substantially improved compared to both BPH and control (p=0.
001 for all), while mean fPSA/tPSA values for PCa were significantly decreased compared to BPH and control values (p=0.
001).
In PCa, the mean +SD value of the DHT ratios was significantly lower than in each BHP, and controls (P<0.
001) were significantly lower in PCa than in each BHP and regulation (P<0.
001).
The mean DHT values for BPH were significantly higher as compared to control values (p< 0.
001).
Conclusion: The level of serum tPSA is 4.
2 ng/ml for prostate tumor screening, while 10.
1 ng/ml for PCa and BPH differentiation.

Related Results

Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Biochemical and Histopathological evaluation of prostatic tissue under effect of Pterostilbene in benign prostatic hyperplasia rat model
Biochemical and Histopathological evaluation of prostatic tissue under effect of Pterostilbene in benign prostatic hyperplasia rat model
Background: Benign prostatic hyperplasia [BPH] is the urologic condition that affects elderly men the most frequently Benign prostatic hyperplasia. Benign prostatic hyperplasia mus...
Diagnostic Accuracy of Prostatic Specific Antigen Densityin Different Prostatic Disorders
Diagnostic Accuracy of Prostatic Specific Antigen Densityin Different Prostatic Disorders
Objective: To determine the diagnostic accuracy of PSA density in Prostate Cancer, Benign Prostatic Hyperplasia (BPH) and Prostatitis, taking biopsy as the gold standard. Stu...
Types of the prostate blood supply during super-selective embolization of prostatic arteries
Types of the prostate blood supply during super-selective embolization of prostatic arteries
Introduction. Pelvic arteries have various anatomy and anastomoses with other branches of the internal iliac artery (IIA). This explains the technical complexity of identification ...
Prostate specific antigen in the serum of men ≥ 50 years old with benign prostatic hyperplasia and some related factors
Prostate specific antigen in the serum of men ≥ 50 years old with benign prostatic hyperplasia and some related factors
Background: Men over 50 years old often have lower urinary tract symptoms and most of them are caused by benign prostatic hyperplasia (BPH). The incidence of benign prostatic hyper...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Monotherapy versus combination therapy in the treatment of benign prostatic hyperplasia: A single center study
Monotherapy versus combination therapy in the treatment of benign prostatic hyperplasia: A single center study
Background and objectives: Most benign prostatic hyperplasia patients do not present obvious indicators for surgical intervention, so most of these patients are treated initially w...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...

Back to Top